Besides tumor immune cells, peripheral blood immune status was also crucial and could be used to evaluate the clinical benefits of anti-PD-1/PD-L1 therapy [44, 45]; for example, specific PD-1+ CD56+ and CD8+ T cells frequently indicate a favorable prognosis in patients with melanoma treated with immunotherapy [46]. This evidence concerns the gene CD8A and melanoma.